Gemcitabine‐induced epithelial‐mesenchymal transition‐like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal‐like phenotype
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Gemcitabine‐induced epithelial‐mesenchymal transition‐like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal‐like phenotype
Authors
Keywords
-
Journal
MOLECULAR CARCINOGENESIS
Volume 58, Issue 11, Pages 1985-1997
Publisher
Wiley
Online
2019-08-02
DOI
10.1002/mc.23090
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer
- (2018) Eric Van Cutsem et al. INTERNATIONAL JOURNAL OF CANCER
- Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic adenocarcinoma
- (2018) Manoj Amrutkar et al. PANCREATOLOGY
- MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model
- (2018) Kei Kawaguchi et al. TISSUE & CELL
- Cisplatin-induced ERK1/2 activity promotes G1 to S phase progression which leads to chemoresistance of ovarian cancer cells
- (2018) Michal Kielbik et al. Oncotarget
- EMT: Present and future in clinical oncology
- (2017) Patricia G. Santamaria et al. Molecular Oncology
- Pancreatic cancer heterogeneity and response to Mek inhibition
- (2017) K Pedersen et al. ONCOGENE
- Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer
- (2017) Niranjan Awasthi et al. Oncotarget
- mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer
- (2016) David R. Driscoll et al. CANCER RESEARCH
- Epithelial–mesenchymal transition: a new target in anticancer drug discovery
- (2016) Fabrizio Marcucci et al. NATURE REVIEWS DRUG DISCOVERY
- The ERK–ZEB1 pathway mediates epithelial–mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids
- (2016) L-Y Chiu et al. ONCOGENE
- Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies
- (2016) Tasuku Matsuoka WORLD JOURNAL OF GASTROENTEROLOGY
- CRP2, a new invadopodia actin bundling factor critically promotes breast cancer cell invasion and metastasis
- (2016) Céline Hoffmann et al. Oncotarget
- Role of EMT in Metastasis and Therapy Resistance
- (2016) Bethany Smith et al. Journal of Clinical Medicine
- Tumor Budding: The Name is EMT. Partial EMT.
- (2016) Alexandru Grigore et al. Journal of Clinical Medicine
- Targeting mTOR in Pancreatic Ductal Adenocarcinoma
- (2016) Sentia Iriana et al. Frontiers in Oncology
- Tumor Budding Is an Independent Adverse Prognostic Factor in Pancreatic Ductal Adenocarcinoma
- (2015) Kate O’Connor et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal cells in pancreatic cancer
- (2015) J A Galván et al. BRITISH JOURNAL OF CANCER
- Epithelial-mesenchymal, mesenchymal-epithelial, and endothelial-mesenchymal transitions in malignant tumors: An update
- (2015) Simona Gurzu World Journal of Clinical Cases
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
- (2014) Jeffrey R. Infante et al. EUROPEAN JOURNAL OF CANCER
- Epithelial to mesenchymal transition correlates with tumor budding and predicts prognosis in esophageal squamous cell carcinoma
- (2014) Yukiko Niwa et al. JOURNAL OF SURGICAL ONCOLOGY
- Comparative Proteomic Profiling of Pancreatic Ductal Adenocarcinoma Cell Lines
- (2014) Yikwon Kim et al. MOLECULES AND CELLS
- ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1
- (2014) Peijing Zhang et al. NATURE CELL BIOLOGY
- Oncogenic roles of EMT-inducing transcription factors
- (2014) Alain Puisieux et al. NATURE CELL BIOLOGY
- Targeting EMT in cancer: opportunities for pharmacological intervention
- (2014) Felicity M. Davis et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Crosstalk of Oncogenic Signaling Pathways during Epithelial–Mesenchymal Transition
- (2014) Stephan Lindsey et al. Frontiers in Oncology
- Colon Cancer Cells Escape 5FU Chemotherapy-Induced Cell Death by Entering Stemness and Quiescence Associated with the c-Yes/YAP Axis
- (2013) Y. Touil et al. CLINICAL CANCER RESEARCH
- Tumour budding is a reproducible index for risk stratification of patients with Stage II colon cancer
- (2013) Y.-H. Lai et al. Colorectal Disease
- The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance
- (2013) Florian A. Siebzehnrubl et al. EMBO Molecular Medicine
- Tumor budding as a useful prognostic marker in T1-stage squamous cell carcinoma of the esophagus
- (2013) Hitoshi Teramoto et al. JOURNAL OF SURGICAL ONCOLOGY
- Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer
- (2013) Suguru Yamada et al. SURGERY
- Tumour budding is a strong and independent prognostic factor in pancreatic cancer
- (2012) E. Karamitopoulou et al. EUROPEAN JOURNAL OF CANCER
- Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line
- (2012) Jin Ren et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family
- (2012) N Skrypek et al. ONCOGENE
- A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma
- (2011) Jing Hu et al. Journal of Hematology & Oncology
- Hydroxyurea Decreases Gemcitabine Resistance in Pancreatic Carcinoma Cells With Highly Expressed Ribonucleotide Reductase
- (2011) Naotake Funamizu et al. PANCREAS
- Solitary cell infiltration is a novel indicator of poor prognosis and epithelial-mesenchymal transition in pancreatic cancer
- (2010) Yohei Masugi et al. HUMAN PATHOLOGY
- ZEB1 in Pancreatic Cancer
- (2010) Ulrich Wellner et al. Cancers
- Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
- (2009) T. Arumugam et al. CANCER RESEARCH
- The basics of epithelial-mesenchymal transition
- (2009) Raghu Kalluri et al. JOURNAL OF CLINICAL INVESTIGATION
- The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs
- (2009) Ulrich Wellner et al. NATURE CELL BIOLOGY
- Loss of E-Cadherin Promotes Metastasis via Multiple Downstream Transcriptional Pathways
- (2008) T. T. Onder et al. CANCER RESEARCH
- Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
- (2008) Brian M. Wolpin et al. JOURNAL OF CLINICAL ONCOLOGY
- The regulatory or phosphorylation domain of p120 catenin controls E-cadherin dynamics at the plasma membrane
- (2007) Yuri Fukumoto et al. EXPERIMENTAL CELL RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started